	Myosin-9 mRNA expression	IC_{50} of HHT(ng ml^{-1})
Kasumi-1	1±0.12	16.06±3.17
HL-60	3.36±0.24	16.92±4.22
K562	0.85±0.36	38.42±5.68
U937	2.87±0.47	22.64±5.14
THP-1	4.89±0.54	29.48±6.01
Patients1	7.18±1.03	10.32±2.76
Patients2	4.41±0.85	15.76±3.49
Patients3	2.18±0.28	16.09±4.08

Supplementary table1. The baseline expression of myosin-9 and IC50 values of HHT in AML cells. The level of myosin-9 mRNA in a selection of AML cell lines and human primary hematopoietic stem/progenitor cells was examined by real-time PCR. The myosin-9 mRNA expression in Kasumi-1 was used as control. The data are presented the mean ± S.D. of the results from six independent experiments

Supplementary Method

Quantitative polymerase chain reaction (qPCR)

The expression level of the myosin-9 gene was determined using reverse transcription-qPCR with SYBR Green I [Takara Biotechnology, Dalian, China], and GAPDH was used as a reference gene. Total RNA was extracted using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA) and reverse transcribed into cDNA by a SuperScript II first-strand cDNA synthesis kit (Invitrogen Life Technologies). The reaction system contained 12.5 μl 2X SYBR Premix Ex Taq [Takara Biotechnology], 1 μl cDNAs and 10 pmol of each primer. The reaction was performed at 95 ℃ for 1 min, followed by 40 cycles of denaturation at 95 ℃ for 15 sec and annealing/extension at 60 ℃ for 60 sec, on an iQ5 Real-Time PCR instrument (Bio-Rad Laboratories, Hercules, CA, USA).

The primer sequences were as follows:
Forward,5′-ATGGGGAAGGTGAAGGTCG-3′ and reverse,
5′-GGGTCATTGATGGCAACAATATC-3′ for GAPDH; Forward, 5′-
ACCCGTGGTGGAACTGAC -3′ and reverse, 5′- CATCTACCGACTGGTTGTGA
-3′ for myosin-9.